Igniting the path to sustainable
and affordable innovation
India
Africa
Eastern Europe
Dr. Himabindu Gaddipati, MD, EMTM
Dr. Gaddipati is a clinical oncologist and geneticist with over 2 decades of experience in clinical, scientific, regulatory and commercialization aspects of cancer product development. Throughout her career she has strived to understand the critical gaps along the lifecycle. Through her entrepreneurial ventures Lumiseek Inc and VCR Park she has validated the mechanism for creating exponential value by alignment of key resources, infrastructure and expertise across the value chain. 
James Tai, MBA, MS
James has a diverse life sciences & healthcare background that spans over two decades which includes life sciences venture capital, outpatient provider services, healthcare private equity, and strategy consulting. He sits on the Board of Directors for a variety of innovative life sciences & healthcare companies, and has the opportunity to present at national healthcare conferences. 
Dr. Cyrus Arman, PhD
Dr. Cyrus is a Life Science and Biotechnology executive with 2 decades of expertise in corporate strategy and fund raising. He was a Co-Founder and Managing Partner for BioVega Capital, an event-driven life sciences hedge fund and Vice President, Corporate Development and Strategy for Neuvogen, Inc. Prior to which he served as the director for corporate strategy at Amgen. 
Dr.Mandar Kulkarni, PhD
Dr. Kulkarni has acquired life science focused strategic and business development experience over the tenure of his career spanning two decades. He was an executive team member of a seed stage start-up in New Haven which was followed by leadership roles in several precision oncology companies in India where he routinely collaborated with leading institutions across the country. 
Previous
Next
Through our holistic approach we will
Mission
Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions.
Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics:
E
The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle
S
Ability to boost R&D productivity through operational optimization and process transformation
G
Promote ethical conduct of business and collaboration while ensuring inclusion & diversity
Scope
Scope
EMCIF is the first dedicated fund to address immense global inequity and disparity in cancer care.
What We Do
Our Services
Invest
Invest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D.
Streamline
Streamline the product-market fit and ensure access to supportive infrastructure and resources.
Facilitate
Facilitate their collaborative R&D/commercialization strategy in geographies of interest.
How We Do It
Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by:
Reducing costs through infrastructure consolidation and collaborative expertise
Expanded access to capital
Facilitating rapid market penetration and commercial scaling
Change the Future with Us!
Address: 8885 Rio San Diego Dr
Unit 237, San Diego, CA 92108
United States
